<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>

INVESTOR RELATIONS

Press Releases

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

Apr 13, 2017
Revised model factoring in PCM-075 (AML drug) as the key driver of the company going forward - sets $4 target price.
Apr 12, 2017
Maxim Group upgrades Trovagene from a "hold" position to a "buy" position based on PCM-075 (AML drug candidate) as the key driver of the company going forward
 

email print rss